New Stock News | Shengsheng Cold Chain Submits Listing Application to Hong Kong Stock Exchange Again

According to the disclosure of the Hong Kong Stock Exchange on July 22, Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. (referred to as Shengsheng Cold Chain) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CICC and Sinolink (Hong Kong) as its joint sponsors. The company had previously submitted an application to the Hong Kong Stock Exchange on January 13, 2026. According to the prospectus, Shengsheng Cold Chain is a leading integrated temperature-controlled supply chain service provider in the pharmaceutical and life sciences industry in China, focusing on temperature-controlled supply chain services for clinical trials, extending to temperature-controlled supply chain services for commercial medical products, and the research and manufacturing of temperature-controlled equipment and materials. According to data from Frost & Sullivan, based on revenue in 2025, the company is the largest temperature-controlled supply chain service provider in the pharmaceutical and life sciences industry in China, and is the only Chinese company among the top ten global providers of temperature-controlled supply chain services for clinical trials.